- Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, et al. Bone cancer, version 2. 2017 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2017;15:155-67.
- Coffin C, Fletcher J, Fletcher C, Unni
K, Mertens F. World Health Organization classification of tumours Pathology and genetics of tumours of soft tissue and bone. 2002. www.iarc.fr/who-bluebooks, IARC Press.
- Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, et al. Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma. Front Pharmacol. 2017;8:150.
- Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010;8:705-18.
- Lopes-Júnior LC, Silveira DSC, Vulczak A, dos Santos JC, Veronez LC, Fisch A, et al. Emerging cytokine networks in osteosarcoma. Oncology Communications 2016;2. doi: 10.14800/oc.1167
- Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res 2012;2:14.
- Thiagarajan A, Iyer NG. Radiation-induced sarcomas of the head and neck. World J Clin Oncol 2014;5:973.
- Polyzoidis S, Ashkan K. DCVax®-L—
Developed by Northwest Biotherapeutics. Hum Vaccin Immunother 2014;10:3139-45.
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell 2012;21:309-22.
- Savitskaya YA, Rico-Martínez G, Linares-González LM, Delgado-Cedillo EA, Téllez-Gastelum R, Alfaro-Rodríguez AB, et al. Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res 2012;2:9.
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
- Goldszmid RS, Trinchieri G. The price of immunity. Nat immunol 2012;13:932. doi: 10.1038/ni.2422.
- Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti-cancer therapy. Curr Opin Immunol 2012;24:633-9.
- Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol
2007;7:144.
- Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by γ c family cytokines. Nat Rev Immunol 2009;9:480.
- Sato T, Watanabe K, Masuhara M, Hada N, Hakeda Y. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab 2007;25:19-27.
- ElKassar N, Gress RE. An overview of IL-7 biology and its use in immunotherapy. J Immunotoxicol 2010;7:1-7.
- Al-Rawi M, Mansel R, Jiang WG. Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. Histol and histopathol 2003;18:911-23.
- Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005;19:228-30.
- Kim J-H, Sim JH, Lee S, Seol MA, Ye
S-K, Shin HM, et al. Interleukin-7 induces osteoclast formation via STAT5, independent of receptor activator of NF-kappaB ligand. Front Immunol 2017;8:1376.
- Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA. Interleukin‐7 influences osteoclast function in vivo but is not a critical factor in ovariectomy‐induced bone loss. J Bone Miner Res 2006;21:695-702.
- Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9.
- Mojtahedi Z, Khademi B, Erfani N, Taregh Y, Rafati Z, Malekzadeh M, et al. Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma. Indian J Cancer 2014;51:227.
- Mackay I, Rosen FS, Delves P, Roitt I. The immune system. N Engl J Med 2000;343:37-49.
- Xiao H, Chen L, Luo G, Son H, Prectoni JH, Zheng W. Effect of the cytokine levels in serum on osteosarcoma. Tumor Biol 2014;35:1023-8.
- Roato I, Gorassini E, Brunetti G, Grano M, Ciuffreda L, Mussa A, et al. IL‐7 Modulates Osteoclastogenesis in Patients Affected by Solid Tumors. Ann N Y Acad Sci 2007;1117:377-84.
- Paleri V, Pulimood A, Davies G, Birchall M. Interleukins 7 and 12 are expressed in head and neck squamous cancer. Clin Otolaryngol Allied Sci 2001;26:302-6.
- Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev 2007;16:102-7.
- Toraldo G, Roggia C, Qian W-P, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor κB ligand and tumor necrosis factor α from T cells. Proc Natl Acad Sci U S A 2003;100:125-30.
- Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000;96:1873-8.
- Lee S-K, Kalinowski JF, Jastrzebski SL, Puddington L, Lorenzo JA. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology 2003;144:3524-31.
- Ardekani MTF, Malekzadeh M, Hosseini SV, Bordbar E, Doroudchi M, Ghaderi A. Evaluation of pre-treatment serum levels of IL-7 and GM-CSF in colorectal cancer patients. Int J Mol Cell Med 2014;3:27.
- Bordbar E, Malekzadeh M, Ardekani MTF, Doroudchi M, Ghaderi A. Serum levels of G-CSF and IL-7 in Iranian breast cancer patients. Asian Pac J Cancer Prev 2012;13:5307-12.
- Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, Klaske A, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007;13:2385-91.
- Mengus C, Le Magnen C, Trella E,
Yousef K, Bubendorf L, Provenzano M, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 2011;9:162. 1.
|
